Login / Signup

The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.

Lasair O'CallaghanElizabeth ChertavianScott J JohnsonErin FerriesKristina M Deligiannidis
Published in: Journal of medical economics (2024)
This economic model's results suggest that zuranolone is a more cost-effective therapy compared to SSRIs for treating adults with PPD.
Keyphrases
  • depressive symptoms
  • stem cells
  • sleep quality
  • replacement therapy
  • mesenchymal stem cells
  • cell therapy
  • smoking cessation